Acute and long-term effects of 17 beta-oestradiol on agonist-stimulated force in rat tail artery.
The effects of 17 beta-oestradiol on the force responses to KCI and noradrenaline were investigated in rings of the rat tail artery. Incubation with 10 microM 17 beta-oestradiol for 100-295 min reduced the force amplitude after 5 min in high-K+ (140 mM) to 10% of the control value. The inhibitory effect of the steroid was unaffected by the NO-synthase inhibitor L-NAME. Rings activated by an intermediate degree of depolarization (60 mM K+) were less affected by the steroid (58% of control force). The sustained force response to 1 microM noradrenaline was reduced in the presence of 17 beta-oestradiol to 60% of control value. Lower concentrations of 17 beta-oestradiol (0.1 and 1 microM) were without acute effects on force development. However, longterm effects of 17 beta-oestradiol on vessel reactivity were found at these low concentrations. Rings were cultured for 3-7 days in the absence or in the presence of the steroid before they were stimulated with agonists. Cultured rings developed an increased sensitivity to noradrenaline compared with freshly prepared ones. Cocaine (30 microns) shifted the noradrenaline concentration-response curve to the left in freshly prepared rings while it had no effect in cultured ones, indicating that the increased sensitivity to noradrenaline in cultured rings depends on loss of noradrenaline uptake. Rings cultured for 7 days in the presence of 0.1 microM 17 beta-oestradiol developed a more pronounced supersensitivity to noradrenaline (EC50 for noradrenaline was 0.13 +/- 0.03 microM in steroid exposed rings vs. 0.38 +/- 0.09 microM in control rings). Thus, prolonged treatment with 17 beta-oestradiol results in a potentiation of noradrenaline evoked force, in contrast to the acute effect of the steroid.
Lydrup
M L
ML
Department of Physiology and Neuroscience, University of Lund, Sweden.
Nilsson
B O
BO
D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D003042:Cocaine / Q000494:pharmacology; D003327:Coronary Disease / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology* / Q000502:physiology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000502:physiology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology
D004791:Enzyme Inhibitors; D004958:Estradiol; D011189:Potassium Chloride; D019001:Nitric Oxide Synthase; D003042:Cocaine; D019331:NG-Nitroarginine Methyl Ester; D009638:Norepinephrine